Key facts
- It has raised $71.1M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Addor Capital, Cowin Capital, Oriental Fortune Capital, Zheshang Venture Capital, DPH Capital — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Sumgen
- ·The full record, as it builds
Funding rounds
No funding rounds for Sumgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sumgen
Developer of innovative antibody drugs designed for the treatment of tumors and other diseases. The company offers computer-aided design combined with mammalian cell display technology to screen and optimize antibody drugs for individual candidates and create effective antibody drugs, thereby enabling patients to receive treatment for major diseases such as cancer.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2015
- Employees
- 22
- Website
- sumgenbio.com/
- Ownership
- Privately Held (backing)
Sumgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sumgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sumgen in its N-PORT filings yet. We sweep new filings monthly.